** Fampyra 10 mg prolonged-release tablets.
** Therapeutic indications:
Fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS).
MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves.
The medicine can only be obtained with a prescription.
** Pharmacotherapeutic group:
Other nervous system drugs, ATC code: N07XX07.
** Mechanism of Action:
Fampyra is a potassium channel blocker. By blocking potassium channels, Fampyra reduces the leakage of ionic current through these channels, thereby prolonging repolarization and thus enhancing action potential formation in demyelinated axons and neurological function. Presumably, by enhancing action potential formation, more impulses might be conducted in the central nervous system.
How does Fampyra work?
– For the body’s muscles to contract, electrical impulses are transmitted along the nerves to the muscles. In MS, this transmission of electrical impulses is impaired when the protective sheaths around the nerves become damaged, which can lead to muscle weakness, muscle stiffness and difficulty walking.
– The active substance in Fampyra, fampridine, is a potassium-channel blocker. It acts on damaged nerves, where it prevents charged potassium particles from leaving the nerve cells. This is believed to have the effect of allowing the electrical impulse to continue travelling along the nerves to stimulate the muscles, making it easier to walk.
The recommended dose is one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening). Fampyra should not be administered more frequently or at higher doses than recommended. The tablets should be taken without food.